22 news items
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
BMY
23 May 24
-pulmonary symptoms should be assessed for potential myocarditis. If myocarditis is suspected, withhold dose, promptly initiate high dose steroids
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
ABBV
BMY
17 May 24
to assess antipsychotic treatment efficacy.
“When we compare the two products, we believe emraclidine differentiates by its
Bristol Myers Squibb Presents New 4-Year Sotyktu Data Demonstrate Durable Response Rates And Consistent Safety In Moderate-To-Severe Plaque Psoriasis
BMY
16 May 24
, and 57.2% for static Physician's Global Assessment (sPGA) 0/1 (clear/almost clear), using modified nonresponder imputation (mNRI). The safety profile
New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
BMY
16 May 24
for Psoriasis Area and Severity Index (PASI) 75 and 90 were 71.7% and 47.5%, respectively, and 57.2% for static Physician's Global Assessment (sPGA) 0/1
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
BMY
15 May 24
or complete response per Lugano criteria as assessed by an Independent Review Committee (IRC). The complete response (CR) rate was 73.4% (95% CI: 63.3
io9h4v8iqpro1d98vpkh3zsuzr6hpjzpsm1cslklkctru7gmv1atrcpb5i
BMY
26 Apr 24
on the current state of the company.
Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform
mf0rk16osr893nv19zqjz9xs0na0c
BMY
26 Apr 24
of overall survival (OS) and progression-free survival (PFS) as assessed by Blinded Independent Central Review (BICR). With a median follow up
t1i7illtikupa2gmaf109wsn8rr68538bb
BMY
25 Apr 24
as assessed
4x9bk8pm7h9xqiatokqhvxk
BMY
8 Apr 24
of overall response rate.
The study remains ongoing to assess the additional key secondary endpoint of overall survival.
In 2022
t1fra5ll660t4r422zmpoveqgv72uoxavs8c4go9ij4u
BMY
6 Apr 24
meaningful changes in movement disorder scale scores over 52 weeks (Oral Session: New Pharmacological Treatments and Assessments and Poster F74
ap4b4nw11eolpka7xkr3srydm72i7dacrgr5p0xdsyz7lxm0m3iuyo868db
BMY
2 Apr 24
assessment to understand evolving stakeholder views and ensure its business priorities
xr5de5pesnwx4d3he4x5eaafuzv mz3r2dtv5zw124m1eawj0
BMY
ZLAB
1 Apr 24
).
The study remains ongoing to assess the additional key secondary endpoint of overall survival.
Results showed that Krazati
k3cab7s
BMY
CATX
LNTH
28 Mar 24
feasibility assessments on additional sites.Preliminary results from Cohorts 1 and 2 of the Phase 1/2a trial are expected in the third
bhl6e66tgk6ko7v9o52eshbr83uxol0of
BMY
25 Mar 24
.
Echocardiogram assessments of LVEF are required prior to and during treatment with CAMZYOS. Initiation of CAMZYOS in patients
enfa9fehqrug8z05 zowu4pixbdtvvf4o9
BMY
14 Mar 24
escalation portion of the study assessed the safety and recommended dose for the subsequent Phase 2 expansion cohort. The Phase 2 portion of the study